Hialubrix 30mg/2ml syringe

Traumatic and degenerative joint pathology. Auxiliary in orthopedic surgery.

Active ingredient

Sodium hyaluronate

Composition

Active ingredient: hyaluronic acid; 2 ml of the solution contains 30 mg of sodium salt of hyaluronic acid. Excipients: sodium chloride; sodium dihydrophosphate, dihydrate; sodium hydrophosphate, dodecahydrate; water for injection.

How to take, the dosage

Adults are prescribed 2 ml of the drug by intraarticular injection once a week for 3 weeks. Children. Do not use.

Interaction

Hyaluronic acid interacts with some local anesthetics, prolonging their analgesic effect.

Special Instructions

Disinfectants containing quaternary ammonium salts are not recommended, as contact with hyaluronic acid may result in precipitate formation; intra-articular injection should be performed by competent medical professionals in accordance with the established procedure under aseptic conditions required for this mode of administration. Some patients with inflammatory arthritis (rheumatoid arthritis or gouty arthritis) have experienced a transient increase in inflammation after injection of the drug. In the presence of joint effusion it is recommended to perform aspiration before the injection of Hialubrix. It is recommended not to overload the joint for several hours after injection. Use during pregnancy or lactation. Although no embryonic toxicity or teratogenic effects have been observed in animal experiments, the use of the drug in pregnant and breastfeeding mothers should be limited except in cases that were absolutely necessary according to the physician’s assessment and only after a careful risk/benefit assessment.

Synopsis

Solution for injection. Basic physico-chemical properties: clear viscous solution with no visible foreign inclusions.physico-chemical properties: clear viscous solution with no visible foreign inclusions.

Contraindications

Individual hypersensitivity to the drug components. History of allergy to poultry proteins. Severe liver function disorders.
Intra-articular injections are contraindicated in case of existing infection or skin diseases of the injection site in order to reduce the potential development of septic arthritis.

Side effects

Reactions at the injection site, including discomfort, pain, swelling, redness, irritation, rashes, nodules, pustules, vesicles, hemorrhages, ecchymosis, itching, joint inflammation, synovitis, joint effusion, joint stiffness, joint mobility problems. These symptoms disappear within a few days if you let the joint rest and apply an ice pack. Only in rare cases have such reactions been longer and more serious.

Hypersensitivity reactions, including anaphylactoid reactions, angioedema, skin reactions including rash, itching, erythema, eczema, dermatitis, urticaria; very rarely, anaphylactic shock, but without fatal consequences; serum sickness; fever, feeling of heat, headache, paresthesias.

If the patient has a chronic inflammatory process in the acute stage the use of hyaluronic acid in some individual cases worsened the condition of the patient.
Cases of bacterial arthritis and reactive arthritis in the place of intraarticular injection were observed.

Overdose

No cases of overdose have been reported at this time.

Similarities

Ostenil, Fermatron, GOU-ON, Ostenil Plus, Fermatron Plus, Adant, Heimovis, Hyalripayer-10 Chondroreparant, Armaviscon , Optinol, Hyalon prosthesis